LGVN — Longeveron Inc.

Summary of Longeveron (LGVN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: For the year ended December 31, 2025, Longeveron reported revenues of $1.2 million, a 50% decline from $2.4 million in 2024. This decrease was attributed to lower participant demand for the Bahamas registry trial and reduced contract manufacturing services.
• Expenses: General and administrative expenses rose to approximately $12 million from $10.3 million in 2024, primarily due to increased personnel costs and a one-time severance payment. Research and development expenses increased to $12 million, up from $8.1 million, driven by personnel costs and CMC expenses.
• Net Loss: The net loss for 2025 was approximately $22.7 million, compared to $16 million in 2024, reflecting a 41% increase.
• Cash Position: As of December 31, 2025, cash and cash equivalents stood at $4.7 million, with an additional $15 million raised in a private placement expected to fund operations into Q4 2026.

2. Strategic Updates and Business Highlights:

• Capital Raise: Successfully secured $15 million in new capital from institutional investors, with a potential additional $15 million contingent on meeting milestones.
• Clinical Trials: Enrollment for the pivotal Phase IIb ELPIS II trial in Hypoplastic Left Heart Syndrome (HLHS) was completed in June 2025, with top-line results expected in Q3 2026. The company is preparing for a potential Biologics License Application (BLA) submission based on these results.
• Partnership Strategy: Longeveron aims to pursue strategic partnerships to enhance capital efficiency and accelerate time to market for its therapies, particularly in HLHS and Alzheimer's disease.
• Priority Review Vouchers (PRVs): The HLHS program has been granted rare pediatric disease designation, making it eligible for PRVs, which could be a significant financial opportunity.

3. Forward Guidance and Outlook:

• Clinical Milestones: Anticipated top-line results from the ELPIS II trial in Q3 2026, with plans to initiate a BLA submission if results are favorable. The company is also preparing for a pivotal Phase II trial in Pediatric Dilated Cardiomyopathy (PDCM), expected to start in 2027.
• Partnership Opportunities: Longeveron is actively seeking licensing partners for its Alzheimer's disease program and plans to leverage interest in its aging-related frailty research.

4. Bad News, Challenges, or Points of Concern:

• Declining Revenues: The significant drop in revenue raises concerns about demand for clinical trials and contract manufacturing services.
• Increased Losses: The net loss has widened, indicating potential challenges in managing costs while pursuing growth.
• Regulatory and Development Risks: The success of upcoming clinical trials is critical; any unfavorable results could impact the company's future prospects and ability to secure partnerships.

5. Notable Q&A Insights:

• Manufacturing and CMC: The company is prioritizing manufacturing capabilities and is engaged with a Contract Development and Manufacturing Organization (CDMO) to support future needs.
• PRV Monetization: There is optimism about the potential high value of PRVs, despite concerns about the new sunset date for these vouchers.
• PDCM Study Design: The upcoming PDCM trial aims to demonstrate a meaningful disease-modifying effect, with endpoints focused on reducing the need for heart transplants.
• Female Sexual Dysfunction Program: Longeveron has received a patent for using laromestrocel in treating female sexual dysfunction, which may be pursued as a partnered program due to the high unmet need in this area.

Overall, Longeveron is at a critical juncture with upcoming clinical data expected to shape its future, while navigating financial challenges and seeking strategic partnerships to bolster its growth.